Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients

By News Health
2 hours Ago

(MedPage Today) — SAN FRANCISCO — Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed.
At week 4, Myasthenia Gravis Activities…

Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118255

Author :

Publish date : 2025-10-31 15:11:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Fatal Mix-Ups Spur EMA Warning on Tranexamic Acid Use

Medical Societies Are Facing an Existential Crisis

Drugmakers Recall Antihypertensive Tainted With Cancer-Causing Chemical

Boo! Candy Bars Recalled; JetBlue Passengers Hospitalized; 6 Dead in Food Outbreak

Should We Screen All Newborns for FH?

Full-Year Data Back TYK2 Blocker in Psoriatic Arthritis